Nitric oxide mimetic molecules as therapeutic agents in alzheimer's disease

Gregory R.J. Thatcher, Brian M. Bennett, James N. Reynolds

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Nitric oxide is multifunctional messenger molecule in the brain, playing important roles including in learning and memory and in regulating the expression of trophic factors that may be reduced with aging. Small molecules that mimic the biological activity of NO, NO mimetics, will bypass cholinergic receptor activation and are anticipated to provide multiple pathways of treating and circumventing dementia in Alzheimer's disease. Activation of soluble guanylyl cyclase and cGMP formation in the brain represents one element of effective neuroprotective pathways mediated by NO. Substantial evidence suggests that NO mimetics may display cGMP-dependent and cGMP-independent activity and may operate via multiple biochemical signaling pathways, both to ensure the survival of neurons subjected to stress and also to provide cognition-enabling pathways to circumvent dementia. GT 1061 is an NO mimetic compound currently in clinical trials for Alzheimer's. A survey of current research indicates that NO mimetics will provide a combined neuroprotective and cognition-enabling approach to anti-neurodegenerative therapy.

Original languageEnglish (US)
Pages (from-to)171-182
Number of pages12
JournalCurrent Alzheimer Research
Volume2
Issue number2
DOIs
StatePublished - Apr 2005
Externally publishedYes

Keywords

  • Alzheimer's
  • BDNF
  • cGMP
  • Cognition
  • Dementia
  • Neurodegeneration
  • Nitrate
  • Nitric oxide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Nitric oxide mimetic molecules as therapeutic agents in alzheimer's disease'. Together they form a unique fingerprint.

Cite this